Effect of Slow-release Melatonin (Circadin®) Therapy on Idiopathic RBD: a Pilot Study

Effect of Slow-release Melatonin (Circadin®) Therapy on Idiopathic REM Sleep Behavior Disorder: a Pilot Study

To evaluate effect of slow-release melatonin (Circadin) on REM sleep behavior disorder.

Investigators planned to administer low (2mg) and high (6mg) dose slow-release melatonin and the placebo for 4 weeks and evaluate Clinical Global Impression scale, RBD questionnaire, PSQI, Epworth sleepiness scale, and quality of life questionnaire (SF-36v2) before and after the treatment along with possible side effects and drug compliance.

Inclusion Criteria:

• REM sleep behavior disorder according to ICSD-3 criteria
• No cognitive deficit or symptom of Parkinsonism
• Those with written consent.

Exclusion Criteria:

• who took medication (ex. clonazepam) for REM sleep behavior disorder
• with degenerative neurologic disorder (ex. Parkinson's disease, Multiple System Atrophy, Lewy-body dementia, etc.)
• who took medication that can affect REM sleep behavior disorder (anti-depressant: SSRI, TCA, MAO-inhibitor)
• who is unable to answer questionnaires
• who have hypersensitive reaction to medications
• Pregnant women or breastfeeding
• who are diagnosed with other parasomnia disorder
• with severe medical disorder (severe liver failure, respiratory failure, heart failure, malignant tumor, etc.)